Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, CIBEREHD, Universidad de Alcalá, Madrid, Spain.
Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Gastrointest Endosc. 2024 Apr;99(4):511-524.e6. doi: 10.1016/j.gie.2023.10.042. Epub 2023 Oct 24.
Circumferential endoscopic submucosal dissection (cESD) in the esophagus has been reported to be feasible in small Eastern case series. We assessed the outcomes of cESD in the treatment of early esophageal squamous cell carcinoma (ESCC) in Western countries.
We conducted an international study at 25 referral centers in Europe and Australia using prospective databases. We included all patients with ESCC treated with cESD before November 2022. Our main outcomes were curative resection according to European guidelines and adverse events.
A total of 171 cESDs were performed on 165 patients. En bloc and R0 resections rates were 98.2% (95% confidence interval [CI], 95.0-99.4) and 69.6% (95% CI, 62.3-76.0), respectively. Curative resection was achieved in 49.1% (95% CI, 41.7-56.6) of the lesions. The most common reason for noncurative resection was deep submucosal invasion (21.6%). The risk of stricture requiring 6 or more dilations or additional techniques (incisional therapy/stent) was high (71%), despite the use of prophylactic measures in 93% of the procedures. The rates of intraprocedural perforation, delayed bleeding, and adverse cardiorespiratory events were 4.1%, 0.6%, and 4.7%, respectively. Two patients died (1.2%) of a cESD-related adverse event. Overall and disease-free survival rates at 2 years were 91% and 79%.
In Western referral centers, cESD for ESCC is curative in approximately half of the lesions. It can be considered a feasible treatment in selected patients. Our results suggest the need to improve patient selection and to develop more effective therapies to prevent esophageal strictures.
在东方小病例系列中,已经有报道称食管环形内镜黏膜下剥离术(cESD)是可行的。我们评估了 cESD 在西方国家治疗早期食管鳞状细胞癌(ESCC)的结果。
我们在欧洲和澳大利亚的 25 个转诊中心进行了一项国际研究,使用前瞻性数据库。我们纳入了所有在 2022 年 11 月前接受 cESD 治疗的 ESCC 患者。我们的主要结局是根据欧洲指南进行的根治性切除和不良事件。
共对 165 例患者的 171 例 cESD 进行了治疗。整块切除和 R0 切除率分别为 98.2%(95%可信区间,95.0-99.4)和 69.6%(95%可信区间,62.3-76.0)。根治性切除率为 49.1%(95%可信区间,41.7-56.6)。非根治性切除的最常见原因是黏膜下深层浸润(21.6%)。尽管在 93%的手术中使用了预防性措施,但需要 6 次以上扩张或其他技术(切开治疗/支架)的狭窄风险很高(71%)。术中穿孔、迟发性出血和不良心肺事件的发生率分别为 4.1%、0.6%和 4.7%。两名患者(1.2%)死于与 cESD 相关的不良事件。2 年时的总生存率和无病生存率分别为 91%和 79%。
在西方转诊中心,cESD 治疗 ESCC 的约半数病变可达到根治性。在选择的患者中,可以考虑将其作为一种可行的治疗方法。我们的结果表明,需要改进患者选择,并开发更有效的治疗方法来预防食管狭窄。